185 related articles for article (PubMed ID: 9116609)
1. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
[TBL] [Abstract][Full Text] [Related]
6. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.
Bacigalupo A; Tedone E; Van Lint MT; Trespi G; Lonngren M; Sanna MA; Moro F; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):783-8. PubMed ID: 7920315
[TBL] [Abstract][Full Text] [Related]
7. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group.
Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied N; Fernandez Rañada JM; Mandelli F; Kho P; Kennedy L; Bell AR
Lancet; 1994 Mar; 343(8900):749-53. PubMed ID: 7907729
[TBL] [Abstract][Full Text] [Related]
8. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
10. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
Goral S; Ynares C; Dummer S; Helderman JH
Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus disease in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study.
Maltezou H; Whimbey E; Abi-Said D; Przepiorka D; Champlin R; Goodrich J
Bone Marrow Transplant; 1999 Sep; 24(6):665-9. PubMed ID: 10490734
[TBL] [Abstract][Full Text] [Related]
12. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
[TBL] [Abstract][Full Text] [Related]
13. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group.
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lönnqvist B; Ringdén O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllylä G
Bone Marrow Transplant; 1997 Feb; 19(3):233-6. PubMed ID: 9028551
[TBL] [Abstract][Full Text] [Related]
14. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
[TBL] [Abstract][Full Text] [Related]
15. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
[TBL] [Abstract][Full Text] [Related]
16. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
17. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation.
Szer J; Durrant S; Schwarer AP; Bradstock KF; Gibson J; Arthur C; To LB; Hughes T; Raunow H
Intern Med J; 2004 Mar; 34(3):98-101. PubMed ID: 15030456
[TBL] [Abstract][Full Text] [Related]
18. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
[TBL] [Abstract][Full Text] [Related]
19. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
20. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant.
Prentice HG; Kho P
Bone Marrow Transplant; 1997 Jan; 19(2):135-42. PubMed ID: 9116610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]